This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Journal of Hematology & Oncology Open Access 09 August 2021
-
TAP: a targeted clinical genomics pipeline for detecting transcript variants using RNA-seq data
BMC Medical Genomics Open Access 10 September 2018
-
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Blood Cancer Journal Open Access 19 July 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gough SM, Slape CI, Aplan PD . NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 2011; 118: 6247–6257.
Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118: 3645–3656.
Fasan A, Haferlach C, Alpermann T, Kern W, Haferlach T, Schnittger S . A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene. Leukemia 2012; 27: 245–248.
Taketani T, Taki T, Nakamura T, Kobayashi Y, Ito E, Fukuda S et al. High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes. Leukemia 2010; 24: 1975–1977.
Lavallée V-P, Baccelli I, Krosl J, Wilhelm B, Barabé F, Gendron P et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet 2015; 47: 1030–1037.
Lavallée V-P, Gendron P, Lemieux S, D'Angelo G, Hébert J, Sauvageau G . EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood 2014; 125: 140–143.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL . TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.
Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S et al. NUP98‐NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer 2013; 52: 683–693.
Delgado MD, León J . Myc roles in hematopoiesis and leukemia. Genes Cancer 2010; 1: 605–616.
Salghetti SE, Kim SY, Tansey WP . Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999; 18: 717–726.
Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I . Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5: 56–61.
Bahram F, Von der Lehr N, Cetinkaya C, Larsson LG . c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95: 2104–2110.
Gregory MA, Hann SR . c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20: 2423–2435.
Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
Wu C, Wang S, Xu C, Tyler A, Li X, Andersson C et al. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc. Cell Physiol Biochem 2015; 35: 647–662.
Li Y, Wang J, Li X, Jia Y, Huai L, He K et al. Role of the Wilms' tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms. Oncol Rep 2014; 32: 2680–2686.
Acknowledgements
This work was supported by the Government of Canada through Genome Canada and the Ministère de l’économie, de l’innovation et des exportations du Québec through Génome Québec, with supplementary funds from AmorChem. We thank Muriel Draoui for project coordination and Sophie Corneau for sample coordination, as well as Marianne Arteau and Raphaëlle Lambert at the IRIC genomics platform for RNA sequencing. The dedicated work of BCLQ staff, namely, Giovanni d’Angelo, Claude Rondeau and Sylvie Lavallée, is also acknowledged. GS and JH are recipients of research chairs from the Canada Research Chair program and Industrielle-Alliance (Université de Montréal). BCLQ is supported by grants from the Cancer Research Network of the Fonds de recherche du Québec–Santé. RNA-Seq read mapping and transcript quantification were performed on the supercomputer Briaree from the Université de Montréal, managed by Calcul Québec and Compute Canada. The operation of this supercomputer is funded by the Canada Foundation for Innovation (CFI), NanoQuébec, RMGA and the Fonds de recherche du Québec – Nature et technologies (FRQ-NT). V-PL is supported by a postdoctoral fellowship jointly supported by Hôpital Maisonneuve-Rosemont’s Foundation and by Cole Foundation. Accession codes: GSE49642, GSE52656, GSE62190, GSE66917, GSE67039.
Author contributions
V-PL analyzed the exomes and transcriptomes of all samples, generated the corresponding figures, tables and Supplementary Material, and co-wrote the paper. GS contributed to project conception and coordination, and co-wrote the paper. JH contributed to project conception, analyzed the cytogenetic and FISH studies, provided all the AML samples and edited the manuscript. PG processed the raw NGS data. GB co-developed the analytical pipeline. SL was responsible for supervision of the bioinformatics team and of statistical analyses. IB performed data validation. SG performed immunoblot experiment.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Lavallée, VP., Lemieux, S., Boucher, G. et al. Identification of MYC mutations in acute myeloid leukemias with NUP98–NSD1 translocations. Leukemia 30, 1621–1624 (2016). https://doi.org/10.1038/leu.2016.19
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.19
This article is cited by
-
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Journal of Hematology & Oncology (2021)
-
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
Leukemia (2019)
-
TAP: a targeted clinical genomics pipeline for detecting transcript variants using RNA-seq data
BMC Medical Genomics (2018)
-
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Blood Cancer Journal (2018)
-
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Nature Medicine (2018)